title: [Effect of intermittent presumptive treatment with sulfadoxine-pyrimethamine on the acquisition of anti-VAR2CSA antibodies in pregnant women living in a hypoendemic area in Senegal].
abstract: The impact of intermittent presumptive treatment (IPT) on the immunity of pregnant women in Senegal is still not very well known. We conducted a prospective study at the Roi-Baudouin maternity of Guediawaye in Senegal to assess IgG antibodies production against MSP1, GLURP and DBL5 in pregnant women under IPT. Blood samples were collected from the participating women at inclusion and delivery. Samples were analyzed after centrifugation for the detection of IgG antibodies in sera by Elisa. Informed consent was given by each study participant prior to their inclusion. A total of 101 eligible women aged from 18 to 44 were included in this study. Multigravidae women represented 70.3% of the study population, whereas primigravidae accounted for 29.7%. The IgG level decreased slightly from inclusion to delivery for the women with regard to anti-MSP1 (83.1at inclusion versus 79.5 at delivery, p = 0.52) as well as anti-GLURP-R2 (84.1 at inclusion versus 75.9 at delivery, p = 0.16). After adjustment for number of pregnancies, there was a significant decrease in the production of anti-VAR2CSA between inclusion and delivery (p < 0.05). By reducing the incidence of malaria during pregnancy, IPT reduced the acquisition of placental parasites antibodies suppressors which could delay the development of protective immunity against malaria. The application of IPT in pregnant women would thus be more appropriate in hypoendemic areas where malaria exposure is lower.
authors.affiliation: Service de parasitologie médicale, faculté de médecine de l'université Cheikh-Anta-Diop de Dakar, Dakar Fann, Sénégal.
authors.forename: I
authors.initials: I
authors.lastname: Diouf
authors.forename: R C K
authors.initials: RC
authors.lastname: Tine
authors.forename: J L
authors.initials: JL
authors.lastname: Ndiaye
authors.forename: K
authors.initials: K
authors.lastname: Sylla
authors.forename: B
authors.initials: B
authors.lastname: Faye
authors.forename: M L
authors.initials: ML
authors.lastname: Mengue
authors.forename: O
authors.initials: O
authors.lastname: Faye
authors.forename: Y
authors.initials: Y
authors.lastname: Dieng
authors.forename: A
authors.initials: A
authors.lastname: Gaye
authors.forename: O
authors.initials: O
authors.lastname: Gaye
mesh_terms: D000293:Adolescent; D000328:Adult; D000914:Antibodies, Viral / Q000097:blood*; D000953:Antigens, Protozoan / Q000276:immunology*; D000962:Antimalarials / Q000008:administration & dosage*; D004338:Drug Combinations; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D016778:Malaria, Falciparum / Q000453:epidemiology / Q000276:immunology / Q000517:prevention & control*; D010963:Plasmodium falciparum / Q000276:immunology; D011247:Pregnancy; D015597:Pregnancy Complications, Parasitic / Q000276:immunology / Q000517:prevention & control*; D011446:Prospective Studies; D011739:Pyrimethamine / Q000008:administration & dosage*; D012675:Senegal / Q000453:epidemiology; D013413:Sulfadoxine / Q000008:administration & dosage*
chemical_list: D000914:Antibodies, Viral; D000953:Antigens, Protozoan; D000962:Antimalarials; D004338:Drug Combinations; D007074:Immunoglobulin G; C512601:VAR2CSA protein, Plasmodium falciparum; C001205:fanasil, pyrimethamine drug combination; D013413:Sulfadoxine; D011739:Pyrimethamine